Skip to main content

Table 1 Adverse drug reactions reported through active and passive surveillance and dominant symptoms reported

From: Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania

 

Rufiji District

Kilombero/Ulanga Districts1

Total (%)

Total suspected adverse drug events reported

45

50

95 (100)

Identified through active surveillance

21

30

51 (53.7)

Identified through passive surveillance

24

20

44 (46.3)

Number of cases successfully traced

38

41

79 (83.2)

Of the successfully traced cases:

38

41

N = 79 (100)

Events associated with SP monotherapy

20

33

53 (67.1)

Events associated with AS/SP combination therapy

13

0

13 (16.5)

Events associated with AS monotherapy

1

0

1 (1.3)

Events outside DSS area (excluded)

3

5

8 (10.0)

Events unrelated to SP and/or AS (excluded)

1

3

4 (5.0)

Dominant symptoms reported for those included:

34

33

N = 67 (100)

Body blisters and skin detachment

7

11

18 (26.9)

Body swelling, itching and urticarial rashes

10

6

16 (23.9)

Multiple lésions on mucus membranes

6

7

13 (19.4)

Facial edema, sore mouth/nose conjunctiva

5

4

9 (13.4)

Others1

6

5

11 (16.4)

Deaths

Deaths attributable to SP and/or AS caused ADR

2

4

6 (8.9%)

  1. 1. These include side effects such as headache, lightheadedness, shortness of breath, stomachache, diarrhoea, vomiting and kidney pain.